Exagen’s Earnings Call: Growth Amid Financial Hurdles

Exagen ((XGN)) has held its Q3 earnings call. Read on for the main highlights of the call.

Exagen’s Latest Earnings Call: Balancing Growth with Financial Challenges

Exagen’s recent earnings call presented a mixed sentiment, highlighting both strong operational achievements and financial hurdles. The company reported impressive revenue and volume growth, alongside the successful launch of new products and increased pharma services revenue. However, these positives were tempered by challenges such as the loss of a high ASP account, slower ASP gains, and rising expenses, which indicate areas of concern. While Exagen is experiencing positive operational momentum, these financial challenges create a balanced sentiment for the company’s outlook.

Record Quarter Revenue

Exagen reported a record-breaking fourth-quarter revenue of $17.2 million, marking the highest quarter in the company’s history. This represents a nearly 40% increase over the third quarter of 2024, even after accounting for over $1 million in downside revenue adjustments in the previous year.

Strong Volume Growth

The company achieved its highest-ever testing volume for a third-quarter period, with AVISE CTD testing volume increasing by 15% from the same quarter last year and nearly 2% sequentially. This growth underscores Exagen’s expanding market presence and demand for its testing services.

Expansion of Pharma Services Revenue

Pharma services revenue saw a significant increase, reaching $780,000 in the third quarter. Year-to-date, this revenue totaled $1.2 million, a substantial rise from approximately $100,000 in 2024, reflecting the company’s successful expansion in this sector.

Launch of New Rheumatoid Arthritis Biomarkers

Exagen successfully launched assays for detecting anti-PAD4 antibodies, enhancing its rheumatoid arthritis offerings. This development differentiates Exagen’s product lineup and demonstrates its commitment to innovation in diagnostic solutions.

Continued ASP Expansion

The trailing 12-month average selling price (ASP) for AVISE CTD reached $441, marking a 9% year-over-year increase. This growth in ASP highlights Exagen’s efforts to enhance its pricing strategy and revenue per test.

Loss of High ASP Direct Bill Account

The company faced a setback with the loss of a large high ASP direct bill account, which impacted ASP as the business transitioned to a standard commercial insurance payer mix. This change poses a challenge to maintaining ASP growth.

Slower-than-Expected ASP Gains

Exagen encountered slower-than-anticipated ASP gains due to new biomarker reimbursement not ramping up as quickly as expected, coupled with higher denial rates. These factors have affected the company’s ASP growth trajectory.

Potential Delay in Cash Flow Positivity

While Exagen is on track to deliver between $65 million and $70 million in revenue for 2025, sustained cash flow positivity may be delayed until 2026 due to ASP challenges. This potential delay underscores the financial hurdles the company faces.

Increased Operating Expenses

Operating expenses rose to $13.2 million in the third quarter, up from $11.6 million in the same period last year. This increase is attributed to higher R&D spending and sales territory expansion, reflecting Exagen’s investment in growth and innovation.

Forward-Looking Guidance

Exagen’s forward-looking guidance highlights a robust 19% year-to-date revenue growth, driven by an 8% increase in testing volume and a 9% rise in ASP. The company is on track to achieve $65 million to $70 million in revenue for 2025, with the potential for cash flow positivity at the high end of this range. However, sustained cash flow positivity might be delayed until 2026 due to ASP challenges. Despite these hurdles, Exagen continues to see strong order backlogs and is working on ASP expansion through revenue cycle management and payer education efforts.

In conclusion, Exagen’s earnings call reflects a company navigating a complex landscape of growth and financial challenges. While the company has achieved significant operational milestones, financial hurdles such as ASP challenges and increased expenses present areas of concern. Investors and stakeholders will be keenly watching how Exagen addresses these challenges to sustain its growth trajectory.